ACAAI: Considerable delay seen from Rx to approval for children's biologics
There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and Immunology, held from Nov. 12 to 16 in Phoenix.
A study presented at the American College of Allergy, Asthma and Immunology's annual meeting highlights substantial delays in approving biologic therapies for pediatric patients. Dr. Mark Holland and colleagues from Children's Mercy Hospital in Kansas City studied 326 prescriptions for biologics used to treat atopic conditions in children, analyzing the delay from prescription to final approval.
The most commonly prescribed biologics were omalizumab and dupilumab. Almost 40% of prescriptions requiring prior authorization were denied, with unmet insurance criteria and prerequisite treatment requirements as the leading reasons for denial. The mean time from prescription to approval was 32.65 days. The researchers hope this data will spark a discussion on making the approval process faster and more streamlined, emphasizing that children shouldn't have to wait weeks for care their allergist believes they need immediately.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.